Noroplex (Dimethyl Fumarate)

Dimethyl fumarate activates the Nrf2 cellular pathway, which up‑regulates antioxidant and cytoprotective genes. This reduces oxidative stress and modulates inflammatory cytokine production, providing immunomodulatory and anti‑inflammatory effects that are beneficial in neuro‑inflammatory and dermatologic conditions.

The dosage of Noroplex is determined by the prescribing clinician based on the patient’s condition, disease severity, and individual response. Healthcare professionals follow local prescribing guidelines and adjust the regimen as needed; patients should follow the prescriber’s instructions exactly.

Safety data for dimethyl fumarate during pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks and alternatives with their healthcare provider.

To request Noroplex, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Noroplex (dimethyl fumarate) is an oral disease‑modifying therapy that offers a convenient dosing schedule compared with injectable interferons or glatiramer acetate. It provides comparable efficacy in reducing relapse rates, but its safety profile includes a higher incidence of flushing and lymphopenia, requiring regular blood monitoring.

Noroplex tablets should be stored below 25 °C in their original packaging, protected from moisture and direct sunlight. Keep the container tightly closed and out of reach of children. Do not store in bathrooms or near heat sources.

Noroplex is taken orally as a tablet with a full glass of water. It may be taken with or without food, although taking it with food can lessen flushing. Patients should swallow the tablet whole and not split, crush, or chew it unless instructed otherwise by a healthcare professional.

The most serious risks include severe lymphopenia, which can predispose to opportunistic infections such as progressive multifocal leukoencephalopathy (PML), and potential hepatic injury. Patients should undergo regular blood counts and liver function tests, and any signs of infection or liver problems should be reported promptly.

Noroplex is contraindicated in individuals with known hypersensitivity to dimethyl fumarate or any excipients, those with active severe infections, and patients with severe hepatic impairment. Caution is also advised for pregnant or nursing women, and for patients with a history of serious lymphopenia or PML.